Ishikawa Invests ¥500 Million In Flu Vaccine Maker UMN
This article was originally published in PharmAsia News
Executive SummaryTokyo-based Ishikawa Harima Heavy Industry will invest ¥500 million in Akita-based UMN Pharma and establish a flu vaccine manufacturing joint venture
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.